Table 4 |
||||||
|
Cox Regression Analysis |
||||||
|
Factor |
||||||
|
N with valid Followup times |
39,628 |
24,316 |
39,628 |
|||
|
|
||||||
|
Time to diabetic ketoacidosis |
Time to de novo diabetic ketoacidosisA |
Time to hyperglycemic hyperosmolar syndromeB |
||||
|
|
||||||
|
P value |
Adjusted HR (95% CI) |
P value |
Adjusted HR (95% CI) |
P value |
Adjusted HR (95% CI) |
|
|
|
||||||
|
African American (all other races) |
<0.0001 |
2.00 (1.63–2.48) |
<0.0001 |
3.41 (1.99–5.84) |
4.87 (3.18–7.45) |
|
|
Graft lossB (Absent) |
<0.0001 |
1.63 (1.25–2.12) |
||||
|
Cadaveric Donor (living donor) |
0.027 |
2.14 (1.09–4.19) |
||||
|
Quartiles of Age (vs. >55 years) |
||||||
|
<33 |
<0.0001 |
6.64 (4.59–9.61) |
||||
|
33–44 |
<0.0001 |
4.75 (3.31–6.79) |
2.13 (1.34–3.37) |
|||
|
45–55 |
<0.0001 |
2.16 (1.47–3.17) |
||||
|
Diabetes at listing (vs. absent) |
10.06 (7.60–13.30) |
Excluded |
0.0015 |
2.15 (1.34–3.46) |
||
|
BMI <21.6 vs. >28.3 kg/m2 |
<0.0001 |
1.94 (1.44–2.62) |
2.33 (1.09–5.00) |
|||
|
Recipient HCV Positive (Yes/No) |
0.01 |
2.16 (1.20–3.89) |
||||
|
Year of Transplant |
<0.0001 |
1.49 (1.33–1.67) |
1.49 (1.25–1.78) |
0.001 |
1.73 (1.17–2.56) |
|
|
Pretransplant dialysis (Yes/No) |
<0.0001 |
2.11 (1.42–3.12) |
||||
|
Cause of ESRD (vs. all others) |
||||||
|
Diabetes |
<0.0001 |
10.59 (8.52–13.18) |
Excluded |
|||
|
Maintenance Medications |
||||||
|
Tacrolimus (vs. Cyclosporine) |
0.019 |
2.20 (1.13–4.24) |
||||
|
Interaction Terms |
||||||
|
Tacrolimus*Cadaver Donor |
0.02 |
2.27 (1.17–4.41) |
||||
|
Tacrolimus*Year of Transplant |
0.03 |
0.70 (0.50–0.97) |
||||
|
|
||||||
|
Data given as the number (% of total) mean ± one standard deviation HR = hazard ratios, diabetic ketoacidosis = hospitalization for diabetic ketoacidosis, defined as ICD9 code 250.1x hyperglycemic hyperosmolar syndrome = hyperosmolar hyperglycemic syndrome (non-ketotic hyperosmolor coma), defined as ICD9 code 250.2x Due to the less frequent occurrence of hyperglycemic hyperosmolar syndrome, hyperglycemic hyperosmolar syndrome was not analyzed separately in patients without a prior history of diabetes mellitus (de novo hyperglycemic hyperosmolar syndrome). * = p < 0.01 vs. all other recipients by Chi Square Test vs. recipients without diabetic ketoacidosis A = followup time truncated at three years post transplant ESRD = end-stage renal disease B = time-dependent variable |
||||||
|
Abbott et al. BMC Endocrine Disorders 2003 3:1 doi:10.1186/1472-6823-3-1 |
||||||
